<DOC>
	<DOC>NCT01438164</DOC>
	<brief_summary>Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.</brief_summary>
	<brief_title>Cost-effectiveness of FDG-PET</brief_title>
	<detailed_description>To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.</detailed_description>
	<criteria>Cancer Other malignancy Uncontrolled Diabetes Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>FDG-PET</keyword>
	<keyword>cancer</keyword>
	<keyword>staging</keyword>
	<keyword>Evaluate the cost impact in the evaluation of oncologic patients.</keyword>
</DOC>